The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections. For this purpose, it was subsequently combined with tenofovir disoproxil fumarate (TDF), tenofovir alafenami...
Saved in:
Main Author: | Erik De Clercq |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/17/7/959 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation
by: Serena Spampinato, et al.
Published: (2025-06-01) -
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study
by: Diana Hernández-Sánchez, et al.
Published: (2025-07-01) -
Feasibility and acceptability of persons on long‐acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study
by: Elijah R. Kakande, et al.
Published: (2025-07-01) -
Injection site abscesses associated with commensal and environmental bacteria following intramuscular vaccination in horses
by: S.H. Ryu, et al.
Published: (2025-09-01) -
HIV‐1 testing in the context of expanding PrEP modalities
by: Urvi M. Parikh, et al.
Published: (2025-07-01)